Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Brett King*, Natasha Mesinkovska, Paradi Mirmirani, Suzanne Bruce, Steve Kempers, Emma Guttman-Yassky, Janet L. Roberts, Amy McMichael, Maria Colavincenzo, Colleen Hamilton, Virginia Braman, James V. Cassella

*Corresponding author for this work

Research output: Contribution to journal › Article › peer-review

53 Scopus citations

Fingerprint

Dive into the research topics of 'Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata'. Together they form a unique fingerprint.

Keyphrases

Pharmacology, Toxicology and Pharmaceutical Science